Skip to main content
65°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Jaguar Health Inc
(NQ:
JAGX
)
1.170
-0.060 (-4.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Jaguar Health Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Jaguar Health Completes Final Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea (EID) in Dogs
May 03, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health, Inc. (NASDAQ: JAGX) Featured in Coverage of NobleCon18
April 27, 2022
Via
Investor Brand Network
Exposures
Product Safety
Jaguar Animal Health Announces Commercial Availability of Plant-based Canalevia-CA1 (Crofelemer) Prescription Drug for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
April 27, 2022
Canalevia®-CA1 is the first and only treatment for CID in dogs to receive any type of approval from FDA SAN FRANCISCO, CA / ACCESSWIRE / April 27, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX), under its...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health to Present at the NobleCon18 Investor Conference on April 21, 2022
April 20, 2022
SAN FRANCISCO, CA / ACCESSWIRE / April 20, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, Jaguar's president, founder, and CEO, will present at NobleCon18 - Noble Capital...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Announces Replenishment of New Employee Inducement Plan Under Nasdaq Listing Rule 5635(c)(4)
April 15, 2022
SAN FRANCISCO, CA / ACCESSWIRE / April 15, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's New Employee Inducement Award Plan (the "Inducement...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Animal Health to Host Dinner & Tableside Discussion for U.S. Veterinary Oncologists About Chemotherapy-Induced Diarrhea (CID) in Dogs on April 12th, the Final Day of the Veterinary Cancer Society (VCS) Mid-Year Conference in Puerto Vallarta, Mexico
April 06, 2022
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA Veterinary...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Appointment of Pravin Chaturvedi, Ph.D., as Chief Scientific Officer
April 05, 2022
Dr. Chaturvedi continues to serve as Chair of company's Scientific Advisory Board Dr. Chaturvedi continues to provide leadership to the development of two crofelemer pipeline indications, with...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Enters Exclusive Crofelemer Distribution and License Agreement with Quadri Pharmaceuticals Store for Multiple Target Indications in Middle East Markets
March 31, 2022
Agreement grants Quadri Pharmaceuticals Store exclusive promotional, commercialization, and distribution rights in Bahrain, Kuwait, Qatar, Saudi Arabia, the United Arab Emirates, and Oman for human...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Shares Replay Link for March 14, 2022, Investor Webcast
March 14, 2022
Click here to access webcast replay Core 2022 development initiatives: - Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Provides Company Updates and Reports 2021 Financials
March 11, 2022
Core 2022 development initiatives: - Ongoing operation of Company's OnTarget Phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (CTD) - Initiation and completion in...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health to Host Investor Webcast Monday, March 14th at 8:30 AM Eastern Time Regarding Q4 2021 Financials & Corporate Updates
March 07, 2022
Click here to register for webcast Company plans to file its Annual Report on March 11, 2022 on Form 10-K for the fiscal year ended December 31, 2021 SAN FRANCISCO, CA / ACCESSWIRE / March 7, 2022 /...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, March 6th, During the Western Veterinary Conference (WVC) in Las Vegas
March 01, 2022
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from the FDA U.S. veterinarians,...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Animal Health Seeks MUMS Designation from FDA for Canalevia (Crofelemer) for Treatment of Exercise-induced Diarrhea (EID) in Dogs
February 16, 2022
In December of 2021, FDA conditionally approved Canalevia™-CA1 for treatment of chemotherapy-induced diarrhea in dogs, and the company expects Canalevia could receive FDA conditional approval, under...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Receipt by Napo Therapeutics of Small and Medium Enterprise (SME) Designation from the European Medicines Agency
February 15, 2022
SME status is an important designation for Italy-based Napo Therapeutics' rare/orphan disease business model SAN FRANCISCO, CA and MILAN, ITALY / ACCESSWIRE / February 15, 2022 / Jaguar Health...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Completes Final Major Regulatory Filing for Conditional New Animal Drug Approval of Canalevia (Crofelemer) to Treat Exercise-induced Diarrhea in Dogs
February 10, 2022
Canalevia™ would be first and only FDA-approved plant-based medicine for working dogs that suffer from diarrhea SAN FRANCISCO, CA / ACCESSWIRE / February 10, 2022 / Jaguar Health, Inc. (NASDAQ:JAGX),...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Announces Completion of Third-party, Investigator-Initiated Study of Crofelemer, which is Expected to Support Orphan Drug Designation (ODD) for Crofelemer for Congenital Diarrheal Disorders (CDD)
February 01, 2022
Study results expected to be described in upcoming presentations and publications CDD patients face intestinal failure (IF), similar to patients suffering from short bowel syndrome (SBS) - the priority...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Announces Appointment of Martire Particco, MD, as Chief Medical Officer of Napo Therapeutics
January 24, 2022
Napo Therapeutics is focused on expanding crofelemer access in Europe for treatment of patients suffering from rare diseases - beginning with short bowel syndrome (SBS) For SBS, Napo Therapeutics has...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Provides Corporate Update and Outlines 2022 Milestones
January 13, 2022
2021 was a year of progress for Jaguar Health as the company advanced its key human pipeline initiatives focused on chemotherapy-related diarrhea (CTD) and short bowel syndrome with intestinal failure...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida
January 12, 2022
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from FDA U.S. veterinarians,...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
January 04, 2022
The Canalevia.com website, a resource for veterinarians and dog owners, is now live Canalevia™-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs
December 22, 2021
By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA /...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
December 21, 2021
By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA /...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs
December 20, 2021
SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the name of its majority owned subsidiary changed from Napo EU S.p.A. to Napo Therapeutics...
From
Jaguar Health, Inc.
Via
AccessWire
European Medicines Agency Grants Orphan Drug Designation for Crofelemer to Napo EU, Jaguar Health’s Italian Subsidiary, for Short Bowel Syndrome
December 13, 2021
The recognition of Orphan Drug Designation in Europe for crofelemer for this rare disease is the first key milestone of Napo EU under the company's exclusive license agreement with Jaguar Health SAN...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)
December 10, 2021
Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company’s Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)
December 06, 2021
Content from the discussion will be featured in upcoming "Diarrhea Dialogues: Part 2" SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced it is hosting...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
November 19, 2021
Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Reports 2021 Third Quarter Financial Results
November 17, 2021
Mytesi® prescription volume increased 7.6% in Q3 2021 over Q2 2021 Third quarter 2021 Mytesi net and gross sales were approximately $0.6 million and approximately $3.2 million Company expects to...
From
Jaguar Health, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Product Safety
Regulatory
Jaguar Health's Italian Subsidiary Napo EU Appoints Massimo Mineo General Manager
November 16, 2021
REMINDER: Jaguar to host investor webcast Wednesday, November 17th at 8:30 a.m. Eastern regarding third quarter 2021 financials & business updates; Click here to register for webcast SAN FRANCISCO, CA...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health Investor Webcast Rescheduled for Wednesday, November 17th at 8:30 AM Eastern Time
November 15, 2021
Click here to register for webcast Company plans to file Q3 2021 10-Q on November 17, 2021 SAN FRANCISCO, CA / ACCESSWIRE / November 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.